Potential Clinical and Economic Impact of Switching Branded Medications to Generics

Por Straka, Robert J., Keohane, Denis J., Liu, Larry Z.
Publicado no Am J Ther (2017)

Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial

Por Keohane, Denis, Schwartz, Jeffrey, Gundapaneni, Balarama, Stewart, Michelle, Amass, Leslie
Publicado no Orphanet J Rare Dis (2015)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy

Por Stewart, Michelle, Keohane, Denis, Short, Sarah, Alvir, Jose, Ong, Moh-Lim, Mundayat, Rajiv
Publicado no Orphanet J Rare Dis (2015)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

Por Waddington Cruz, Márcia, Amass, Leslie, Keohane, Denis, Schwartz, Jeffrey, Li, Huihua, Gundapaneni, Balarama
Publicado no Amyloid (2016)

Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy

Por Waddington-Cruz, Marcia, Amass, Leslie, Keohane, Denis, Schwartz, Jeffrey, Gundapaneni, Balarama, Li, Hui Hua
Publicado no Orphanet J Rare Dis (2015)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

Por Schmidt, Hartmut H.‐J., Barroso, Fabio, González‐Duarte, Alejandra, Conceição, Isabel, Obici, Laura, Keohane, Denis, Amass, Leslie
Publicado no Muscle Nerve (2016)